Evidence map›Paper›PMID 38914189›Full record

ArticleAmerican journal of obstetrics and gynecology2025

Amniocentesis in pregnancies at or beyond 24 weeks: an international multicenter study.

Roni Zemet, Mohamad Ali Maktabi, Alexandra Tinfow, Jessica L Giordano, Thomas M Heisler, Qi Yan, Roni Plaschkes, Jenny Stokes, Jennifer M Walsh, Siobhán Corcoran and 17 more

Abstract readMulticenter Study
In one paragraph

Article in American journal of obstetrics and gynecology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Roni ZemetDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. Electronic address: roni.zemetlazar@bcm.edu.
Mohamad Ali MaktabiDepartment of Obstetrics and Gynecology, Baylor College of Medicine, Houston, TX.
Alexandra TinfowDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
Jessica L GiordanoDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
Thomas M HeislerDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
Qi YanDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
Roni PlaschkesDepartment of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
Jenny StokesDepartment of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
Jennifer M WalshDepartment of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
Siobhán CorcoranDepartment of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
Erica SchindewolfThe Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA.
Kendra MillerThe Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA.
Asha N TalatiDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC.
Kristen A MillerDivision of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD.
Karin BlakemoreDivision of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD.
Kate SwansonDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA.
Jana RammDepartment of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Giessen, Germany.
Ivonne BedeiDepartment of Prenatal Diagnosis and Fetal Therapy, Justus-Liebig University, Giessen, Germany.
Teresa N SparksDivision of Maternal-Fetal Medicine, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, CA.
Angie C JelinDivision of Maternal-Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD.
Neeta L VoraDivision of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC.
Juliana S GebbThe Center for Fetal Diagnosis and Treatment, The Children's Hospital of Philadelphia, Philadelphia, PA.
David A CrosbyDepartment of Obstetrics and Gynaecology, National Maternity Hospital, Dublin, Ireland.
Michal BerkenstadtThe Danek Gertner Institute of Human Genetics, Sheba Medical Center, Tel-Hashomer, Israel.
Boaz WeiszDepartment of Obstetrics and Gynecology, Sheba Medical Center, Tel-Hashomer, Israel.
Ronald J WapnerDepartment of Obstetrics and Gynecology, Columbia University Irving Medical Center, New York, NY.
Ignatia B Van Den VeyverDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX; Division of Maternal-Fetal Medicine and Reproductive and Prenatal Genetics, Department of Obstetrics and Gynecology, Baylor College of Medicine and Texas Children's Fetal Center, Houston, TX. Electronic address: iveyver@bcm.edu.

Funding

Prenatal Genetic Diagnosis by Genomic Sequencing: A Prospective EvaluationR01HD055651 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Wendy K Chung, Vaidehi Jobanputra · 2007 to 2026
$16.5M
MEDICAL GENETICS RESEARCH FELLOWSHIP PROGRAMT32GM007526 · NIGMS · BAYLOR COLLEGE OF MEDICINE · PI Brendan Lee · 1985 to 2026
$11.4M
Preclinical and Clincial OutcomesP50HD103555 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI MIRJANA MALETIC-SAVATIC · 2020 to 2026
$9.9M
Unmet Needs: Achieving Equity and Support for Parents Pursuing Prenatal Diagnosis in the Genomic EraR01HD105868 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI VORA, NEETA L · 2021 to 2025
$3.4M
Single gene pathogenic variants associated with BEEC (Bladder Exstrophy, Epispadias, Complex)K23DK119949 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI JELIN, ANGIE CHILD · 2019 to 2023
$1.1M
NICHD NIH HHS P50 HD103555NICHD NIH HHS R01 HD055651NICHD NIH HHS R01 HD105868NIDDK NIH HHS K23 DK119949NIGMS NIH HHS T32 GM007526
6 · The paper itself

Abstract

backgroundAmniocentesis for genetic diagnosis is most commonly done between 15 and 22 weeks of gestation but can be performed at later gestational ages. The safety and genetic diagnostic accuracy of amniocentesis have been well-established through numerous large-scale multicenter studies for procedures before 24 weeks, but comprehensive data on late amniocentesis remain sparse.

objectiveTo evaluate the indications, diagnostic yield, safety, and maternal and fetal outcomes associated with amniocentesis performed at or beyond 24 weeks of gestation. STUDY

designWe conducted an international multicenter retrospective cohort study examining pregnant individuals who underwent amniocentesis for prenatal diagnostic testing at gestational ages between 24w0d and 36w6d. The study, spanning from 2011 to 2022, involved 9 referral centers. We included singleton or twin pregnancies with documented outcomes, excluding cases where other invasive procedures were performed during pregnancy or if amniocentesis was conducted for obstetric indications. We analyzed indications for late amniocentesis, types of genetic tests performed, their results, and the diagnostic yield, along with pregnancy outcomes and postprocedure complications.

resultsOf the 752 pregnant individuals included in our study, late amniocentesis was primarily performed for the prenatal diagnosis of structural anomalies (91.6%), followed by suspected fetal infection (2.3%) and high-risk findings from cell-free DNA screening (1.9%). The median gestational age at the time of the procedure was 28w5d, and 98.3% of pregnant individuals received results of genetic testing before birth or pregnancy termination. The diagnostic yield was 22.9%, and a diagnosis was made 2.4 times more often for fetuses with anomalies in multiple organ systems (36.4%) compared to those with anomalies in a single organ system (15.3%). Additionally, the diagnostic yield varied depending on the specific organ system involved, with the highest yield for musculoskeletal anomalies (36.7%) and hydrops fetalis (36.4%) when a single organ system or entity was affected. The most prevalent genetic diagnoses were aneuploidies (46.8%), followed by copy number variants (26.3%) and monogenic disorders (22.2%). The median gestational age at delivery was 38w3d, with an average of 59 days between the procedure and delivery date. The overall complication rate within 2 weeks postprocedure was 1.2%. We found no significant difference in the rate of preterm delivery between pregnant individuals undergoing amniocentesis between 24 and 28 weeks and those between 28 and 32 weeks, reinforcing the procedure's safety across these gestational periods.

conclusionLate amniocentesis, at or after 24 weeks of gestation, especially for pregnancies complicated by multiple congenital anomalies, has a high diagnostic yield and a low complication rate, underscoring its clinical utility. It provides pregnant individuals and their providers with a comprehensive diagnostic evaluation and results before delivery, enabling informed counseling and optimized perinatal and neonatal care planning.

Indexed as

AmniocentesisGestational AgeAdultFemaleGenetic TestingHumansPregnancyPregnancy OutcomePregnancy Trimester, SecondPrenatal DiagnosisRetrospective Studieschromosomal microarray analysisexome sequencingfetal anomaliesgenetic testinglate amniocentesisnext-generation sequencing panelprenatal diagnosispreterm birththird trimester amniocentesis

Identifiers

PMID38914189
PMCPMC11663227

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.